#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=3 .
1-1	0-1	3	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Discussion
2-1	4-14	Discussion	abstract	new	_	_

#Text=Increased selectivity and efficacy can be achieved by linking cytotoxic anticancer drugs to specific target/carrier molecules .
3-1	15-24	Increased	abstract[3]	new[3]	coref	6-13[0_3]
3-2	25-36	selectivity	abstract[3]	new[3]	_	_
3-3	37-40	and	_	_	_	_
3-4	41-49	efficacy	abstract	new	_	_
3-5	50-53	can	_	_	_	_
3-6	54-56	be	_	_	_	_
3-7	57-65	achieved	_	_	_	_
3-8	66-68	by	_	_	_	_
3-9	69-76	linking	_	_	_	_
3-10	77-86	cytotoxic	abstract|substance[7]	new|new[7]	coref|coref|coref|coref	5-15|5-14[34_7]|5-15|5-14[34_7]
3-11	87-97	anticancer	abstract|substance[7]	new|new[7]	coref	5-16
3-12	98-103	drugs	substance[7]	new[7]	_	_
3-13	104-106	to	_	_	_	_
3-14	107-115	specific	object[9]	new[9]	coref	8-4[59_9]
3-15	116-130	target/carrier	substance|object[9]	new|new[9]	_	_
3-16	131-140	molecules	object[9]	new[9]	_	_
3-17	141-142	.	_	_	_	_

#Text=Successful examples of this treatment strategy are antibody-drug conjugates , which target cancer cells due to increased expression of specific proteins , and folate conjugates , which utilize a commonly high expression of the folate receptor ( FR ) on the surface of different human cancer cells .
4-1	143-153	Successful	object[10]	new[10]	coref	4-8[13_10]
4-2	154-162	examples	object[10]	new[10]	_	_
4-3	163-165	of	object[10]	new[10]	_	_
4-4	166-170	this	object[10]|event[12]	new[10]|new[12]	_	_
4-5	171-180	treatment	object[10]|abstract|event[12]	new[10]|new|new[12]	coref	7-12[51_0]
4-6	181-189	strategy	object[10]|event[12]	new[10]|new[12]	_	_
4-7	190-193	are	_	_	_	_
4-8	194-207	antibody-drug	object[13]	giv[13]	coref	4-24[19_13]
4-9	208-218	conjugates	object[13]	giv[13]	_	_
4-10	219-220	,	_	_	_	_
4-11	221-226	which	_	_	_	_
4-12	227-233	target	abstract	new	coref|none	22-1[164_0]|4-12[0_164]
4-13	234-240	cancer	abstract|object[15]	new|new[15]	coref|coref|coref|coref	4-46|4-44[26_15]|4-46|4-44[26_15]
4-14	241-246	cells	object[15]	new[15]	_	_
4-15	247-250	due	_	_	_	_
4-16	251-253	to	_	_	_	_
4-17	254-263	increased	abstract[16]	new[16]	_	_
4-18	264-274	expression	abstract[16]	new[16]	_	_
4-19	275-277	of	abstract[16]	new[16]	_	_
4-20	278-286	specific	abstract[16]|substance[17]	new[16]|new[17]	_	_
4-21	287-295	proteins	abstract[16]|substance[17]	new[16]|new[17]	_	_
4-22	296-297	,	abstract[16]	new[16]	_	_
4-23	298-301	and	abstract[16]	new[16]	_	_
4-24	302-308	folate	abstract[16]|substance|object[19]	new[16]|new|giv[19]	coref|coref|coref|coref	4-35|14-5[99_19]|4-35|14-5[99_19]
4-25	309-319	conjugates	abstract[16]|object[19]	new[16]|giv[19]	_	_
4-26	320-321	,	_	_	_	_
4-27	322-327	which	_	_	_	_
4-28	328-335	utilize	_	_	_	_
4-29	336-337	a	abstract[20]	new[20]	_	_
4-30	338-346	commonly	abstract[20]	new[20]	_	_
4-31	347-351	high	abstract[20]	new[20]	_	_
4-32	352-362	expression	abstract[20]	new[20]	_	_
4-33	363-365	of	abstract[20]	new[20]	_	_
4-34	366-369	the	abstract[20]|substance[22]	new[20]|new[22]	_	_
4-35	370-376	folate	abstract[20]|substance|substance[22]	new[20]|giv|new[22]	_	_
4-36	377-385	receptor	abstract[20]|substance[22]	new[20]|new[22]	_	_
4-37	386-387	(	_	_	_	_
4-38	388-390	FR	abstract	new	_	_
4-39	391-392	)	_	_	_	_
4-40	393-395	on	_	_	_	_
4-41	396-399	the	place[24]	new[24]	_	_
4-42	400-407	surface	place[24]	new[24]	_	_
4-43	408-410	of	place[24]	new[24]	_	_
4-44	411-420	different	place[24]|object[26]	new[24]|giv[26]	coref	6-30[47_26]
4-45	421-426	human	place[24]|object[26]	new[24]|giv[26]	_	_
4-46	427-433	cancer	place[24]|abstract|object[26]	new[24]|giv|giv[26]	coref	6-31
4-47	434-439	cells	place[24]|object[26]	new[24]|giv[26]	_	_
4-48	440-441	.	_	_	_	_

#Text=Warburg effect targeting is another promising strategy for the design and synthesis of new cytotoxic anticancer drugs .
5-1	442-449	Warburg	place|abstract[28]	new|new[28]	coref|coref|coref|coref	4-12[0_28]|9-4|4-12[0_28]|9-4
5-2	450-456	effect	abstract[28]	new[28]	_	_
5-3	457-466	targeting	_	_	_	_
5-4	467-469	is	_	_	_	_
5-5	470-477	another	abstract[29]	giv[29]	coref	9-2[63_0]
5-6	478-487	promising	abstract[29]	giv[29]	_	_
5-7	488-496	strategy	abstract[29]	giv[29]	_	_
5-8	497-500	for	abstract[29]	giv[29]	_	_
5-9	501-504	the	abstract[29]|abstract[30]	giv[29]|new[30]	_	_
5-10	505-511	design	abstract[29]|abstract[30]	giv[29]|new[30]	_	_
5-11	512-515	and	abstract[29]	giv[29]	_	_
5-12	516-525	synthesis	abstract[29]|abstract[31]	giv[29]|new[31]	_	_
5-13	526-528	of	abstract[29]|abstract[31]	giv[29]|new[31]	_	_
5-14	529-532	new	abstract[29]|abstract[31]|substance[34]	giv[29]|new[31]|giv[34]	coref	6-9[39_34]
5-15	533-542	cytotoxic	abstract[29]|abstract[31]|abstract|substance[34]	giv[29]|new[31]|giv|giv[34]	coref	6-9
5-16	543-553	anticancer	abstract[29]|abstract[31]|abstract|substance[34]	giv[29]|new[31]|giv|giv[34]	_	_
5-17	554-559	drugs	abstract[29]|abstract[31]|substance[34]	giv[29]|new[31]|giv[34]	_	_
5-18	560-561	.	_	_	_	_

#Text=Here , the conjugation of sugar residues to cytotoxic drugs shall increase selectivity to cancerous tissues and reduce side effects in patients due to a higher sugar uptake by the cancer cells .
6-1	562-566	Here	_	_	_	_
6-2	567-568	,	_	_	_	_
6-3	569-572	the	abstract[35]	new[35]	_	_
6-4	573-584	conjugation	abstract[35]	new[35]	_	_
6-5	585-587	of	abstract[35]	new[35]	_	_
6-6	588-593	sugar	abstract[35]|substance|substance[37]	new[35]|new|new[37]	coref|coref|coref|coref	6-27|13-14[94_37]|6-27|13-14[94_37]
6-7	594-602	residues	abstract[35]|substance[37]	new[35]|new[37]	_	_
6-8	603-605	to	abstract[35]|substance[37]	new[35]|new[37]	_	_
6-9	606-615	cytotoxic	abstract[35]|substance[37]|abstract|substance[39]	new[35]|new[37]|giv|giv[39]	_	_
6-10	616-621	drugs	abstract[35]|substance[37]|substance[39]	new[35]|new[37]|giv[39]	_	_
6-11	622-627	shall	_	_	_	_
6-12	628-636	increase	_	_	_	_
6-13	637-648	selectivity	abstract	giv	coref	12-12[86_0]
6-14	649-651	to	_	_	_	_
6-15	652-661	cancerous	event[41]	new[41]	_	_
6-16	662-669	tissues	event[41]	new[41]	_	_
6-17	670-673	and	_	_	_	_
6-18	674-680	reduce	_	_	_	_
6-19	681-685	side	abstract[42]	new[42]	coref	11-20[82_42]
6-20	686-693	effects	abstract[42]	new[42]	_	_
6-21	694-696	in	_	_	_	_
6-22	697-705	patients	person[43]	new[43]	_	_
6-23	706-709	due	person[43]	new[43]	_	_
6-24	710-712	to	_	_	_	_
6-25	713-714	a	abstract[45]	new[45]	coref	15-33[113_45]
6-26	715-721	higher	abstract[45]	new[45]	_	_
6-27	722-727	sugar	substance|abstract[45]	giv|new[45]	_	_
6-28	728-734	uptake	abstract[45]	new[45]	_	_
6-29	735-737	by	abstract[45]	new[45]	_	_
6-30	738-741	the	abstract[45]|object[47]	new[45]|giv[47]	coref	10-17[77_47]
6-31	742-748	cancer	abstract[45]|abstract|object[47]	new[45]|giv|giv[47]	coref	7-23[56_0]
6-32	749-754	cells	abstract[45]|object[47]	new[45]|giv[47]	_	_
6-33	755-756	.	_	_	_	_

#Text=To date one sugar-conjugated molecule glufosfamide is in clinical development for the treatment of lung , ovary , pancreatic , brain and CNS cancer as well as soft tissue sarcoma .
7-1	757-759	To	_	_	_	_
7-2	760-764	date	_	_	_	_
7-3	765-768	one	substance[49]	new[49]	_	_
7-4	769-785	sugar-conjugated	substance[49]	new[49]	_	_
7-5	786-794	molecule	abstract|substance[49]	new|new[49]	coref	16-10[120_0]
7-6	795-807	glufosfamide	substance[49]	new[49]	_	_
7-7	808-810	is	_	_	_	_
7-8	811-813	in	_	_	_	_
7-9	814-822	clinical	abstract[50]	new[50]	_	_
7-10	823-834	development	abstract[50]	new[50]	_	_
7-11	835-838	for	abstract[50]	new[50]	_	_
7-12	839-842	the	abstract[50]|abstract[51]	new[50]|giv[51]	_	_
7-13	843-852	treatment	abstract[50]|abstract[51]	new[50]|giv[51]	_	_
7-14	853-855	of	abstract[50]|abstract[51]	new[50]|giv[51]	_	_
7-15	856-860	lung	abstract[50]|abstract[51]|object	new[50]|giv[51]|new	_	_
7-16	861-862	,	abstract[50]|abstract[51]	new[50]|giv[51]	_	_
7-17	863-868	ovary	abstract[50]|abstract[51]|place	new[50]|giv[51]|new	_	_
7-18	869-870	,	abstract[50]|abstract[51]	new[50]|giv[51]	_	_
7-19	871-881	pancreatic	abstract[50]|abstract[51]|object	new[50]|giv[51]|new	_	_
7-20	882-883	,	abstract[50]|abstract[51]	new[50]|giv[51]	_	_
7-21	884-889	brain	abstract[50]|abstract[51]|object	new[50]|giv[51]|new	_	_
7-22	890-893	and	abstract[50]|abstract[51]	new[50]|giv[51]	_	_
7-23	894-897	CNS	abstract[50]|abstract[51]|abstract[56]	new[50]|giv[51]|giv[56]	coref	9-3[0_56]
7-24	898-904	cancer	abstract[50]|abstract[51]|abstract[56]	new[50]|giv[51]|giv[56]	_	_
7-25	905-907	as	abstract[50]|abstract[51]	new[50]|giv[51]	_	_
7-26	908-912	well	abstract[50]|abstract[51]	new[50]|giv[51]	_	_
7-27	913-915	as	abstract[50]|abstract[51]	new[50]|giv[51]	_	_
7-28	916-920	soft	abstract[50]|abstract[51]|abstract[58]	new[50]|giv[51]|new[58]	_	_
7-29	921-927	tissue	abstract[50]|abstract[51]|object|abstract[58]	new[50]|giv[51]|new|new[58]	coref	27-18[224_0]
7-30	928-935	sarcoma	abstract[50]|abstract[51]|abstract[58]	new[50]|giv[51]|new[58]	_	_
7-31	936-937	.	_	_	_	_

#Text=In addition , different sugar-conjugated molecules are currently evaluated preclinically .
8-1	938-940	In	_	_	_	_
8-2	941-949	addition	_	_	_	_
8-3	950-951	,	_	_	_	_
8-4	952-961	different	object[59]	giv[59]	coref	13-3[91_59]
8-5	962-978	sugar-conjugated	object[59]	giv[59]	_	_
8-6	979-988	molecules	object[59]	giv[59]	_	_
8-7	989-992	are	_	_	_	_
8-8	993-1002	currently	_	_	_	_
8-9	1003-1012	evaluated	_	_	_	_
8-10	1013-1026	preclinically	_	_	_	_
8-11	1027-1028	.	_	_	_	_

#Text=In prostate cancer Warburg effect was observed specifically in metastatic tumors which makes glucose-derived chemotherapeutics promising in the treatment of metastatic CRPC .
9-1	1029-1031	In	_	_	_	_
9-2	1032-1040	prostate	abstract|abstract[63]	new|giv[63]	coref|coref|coref|coref	10-18|12-5[85_63]|10-18|12-5[85_63]
9-3	1041-1047	cancer	abstract|abstract[63]	giv|giv[63]	coref	10-19
9-4	1048-1055	Warburg	place|abstract[63]	giv|giv[63]	coref	26-11
9-5	1056-1062	effect	abstract[63]	giv[63]	_	_
9-6	1063-1066	was	_	_	_	_
9-7	1067-1075	observed	_	_	_	_
9-8	1076-1088	specifically	_	_	_	_
9-9	1089-1091	in	_	_	_	_
9-10	1092-1102	metastatic	object[64]	new[64]	coref	27-14[223_64]
9-11	1103-1109	tumors	object[64]	new[64]	_	_
9-12	1110-1115	which	_	_	_	_
9-13	1116-1121	makes	_	_	_	_
9-14	1122-1137	glucose-derived	abstract[65]	new[65]	_	_
9-15	1138-1155	chemotherapeutics	abstract[65]	new[65]	_	_
9-16	1156-1165	promising	_	_	_	_
9-17	1166-1168	in	_	_	_	_
9-18	1169-1172	the	abstract[66]	new[66]	coref	27-11[221_66]
9-19	1173-1182	treatment	abstract[66]	new[66]	_	_
9-20	1183-1185	of	abstract[66]	new[66]	_	_
9-21	1186-1196	metastatic	abstract[66]|abstract[67]	new[66]|new[67]	_	_
9-22	1197-1201	CRPC	abstract[66]|abstract[67]	new[66]|new[67]	_	_
9-23	1202-1203	.	_	_	_	_

#Text=In our research , we found the derivatives of natural 1,4-naphtoquinone compounds to be active in drug-resistant prostate cancer cells .
10-1	1204-1206	In	_	_	_	_
10-2	1207-1210	our	person|abstract[69]	acc|new[69]	ana|ana	10-5|10-5
10-3	1211-1219	research	abstract[69]	new[69]	_	_
10-4	1220-1221	,	_	_	_	_
10-5	1222-1224	we	person	giv	ana	12-3
10-6	1225-1230	found	_	_	_	_
10-7	1231-1234	the	object[71]	new[71]	coref	22-9[168_71]
10-8	1235-1246	derivatives	object[71]	new[71]	_	_
10-9	1247-1249	of	object[71]	new[71]	_	_
10-10	1250-1257	natural	object[71]|substance[73]	new[71]|new[73]	coref	11-9[79_73]
10-11	1258-1275	1,4-naphtoquinone	object[71]|person|substance[73]	new[71]|new|new[73]	_	_
10-12	1276-1285	compounds	object[71]|substance[73]	new[71]|new[73]	_	_
10-13	1286-1288	to	_	_	_	_
10-14	1289-1291	be	_	_	_	_
10-15	1292-1298	active	_	_	_	_
10-16	1299-1301	in	_	_	_	_
10-17	1302-1316	drug-resistant	person|object[77]	new|giv[77]	coref|coref	11-16[80_77]|11-16[80_77]
10-18	1317-1325	prostate	place|object[77]	giv|giv[77]	coref	21-15
10-19	1326-1332	cancer	abstract|object[77]	giv|giv[77]	coref	21-16
10-20	1333-1338	cells	object[77]	giv[77]	_	_
10-21	1339-1340	.	_	_	_	_

#Text=Preliminary data , however , have shown that these substances are also rather cytotoxic for non-cancerous cells , suggesting undesired side effects in vivo .
11-1	1341-1352	Preliminary	abstract[78]	new[78]	_	_
11-2	1353-1357	data	abstract[78]	new[78]	_	_
11-3	1358-1359	,	_	_	_	_
11-4	1360-1367	however	_	_	_	_
11-5	1368-1369	,	_	_	_	_
11-6	1370-1374	have	_	_	_	_
11-7	1375-1380	shown	_	_	_	_
11-8	1381-1385	that	_	_	_	_
11-9	1386-1391	these	substance[79]	giv[79]	coref	12-15[87_79]
11-10	1392-1402	substances	substance[79]	giv[79]	_	_
11-11	1403-1406	are	_	_	_	_
11-12	1407-1411	also	_	_	_	_
11-13	1412-1418	rather	_	_	_	_
11-14	1419-1428	cytotoxic	_	_	_	_
11-15	1429-1432	for	_	_	_	_
11-16	1433-1446	non-cancerous	object[80]	giv[80]	coref	12-18[89_80]
11-17	1447-1452	cells	object[80]	giv[80]	_	_
11-18	1453-1454	,	_	_	_	_
11-19	1455-1465	suggesting	_	_	_	_
11-20	1466-1475	undesired	abstract[82]	giv[82]	_	_
11-21	1476-1480	side	abstract|abstract[82]	new|giv[82]	coref	28-13
11-22	1481-1488	effects	abstract[82]	giv[82]	_	_
11-23	1489-1491	in	abstract[82]	giv[82]	_	_
11-24	1492-1496	vivo	abstract[82]	giv[82]	_	_
11-25	1497-1498	.	_	_	_	_

#Text=Therefore , we utilized the Warburg effect in order to increase the selectivity of the compounds towards tumor cells .
12-1	1499-1508	Therefore	_	_	_	_
12-2	1509-1510	,	_	_	_	_
12-3	1511-1513	we	person	giv	ana	13-1
12-4	1514-1522	utilized	_	_	_	_
12-5	1523-1526	the	abstract[85]	giv[85]	coref	22-5[166_85]
12-6	1527-1534	Warburg	person|abstract[85]	new|giv[85]	_	_
12-7	1535-1541	effect	abstract[85]	giv[85]	_	_
12-8	1542-1544	in	_	_	_	_
12-9	1545-1550	order	_	_	_	_
12-10	1551-1553	to	_	_	_	_
12-11	1554-1562	increase	_	_	_	_
12-12	1563-1566	the	abstract[86]	giv[86]	coref	21-10[158_86]
12-13	1567-1578	selectivity	abstract[86]	giv[86]	_	_
12-14	1579-1581	of	abstract[86]	giv[86]	_	_
12-15	1582-1585	the	abstract[86]|substance[87]	giv[86]|giv[87]	coref	21-6[157_87]
12-16	1586-1595	compounds	abstract[86]|substance[87]	giv[86]|giv[87]	_	_
12-17	1596-1603	towards	abstract[86]|substance[87]	giv[86]|giv[87]	_	_
12-18	1604-1609	tumor	abstract[86]|substance[87]|abstract|object[89]	giv[86]|giv[87]|new|giv[89]	coref|coref	22-40[178_89]|22-40[178_89]
12-19	1610-1615	cells	abstract[86]|substance[87]|object[89]	giv[86]|giv[87]|giv[89]	_	_
12-20	1616-1617	.	_	_	_	_

#Text=We synthesized hybrid molecules , which contain selected natural 1,4-naphtoquinone moieties conjugated with glucose residues via non-glycoside bond at C6 position .
13-1	1618-1620	We	person	giv	ana	18-15
13-2	1621-1632	synthesized	_	_	_	_
13-3	1633-1639	hybrid	object[91]	giv[91]	coref	15-38[114_91]
13-4	1640-1649	molecules	object[91]	giv[91]	_	_
13-5	1650-1651	,	_	_	_	_
13-6	1652-1657	which	_	_	_	_
13-7	1658-1665	contain	_	_	_	_
13-8	1666-1674	selected	_	_	_	_
13-9	1675-1682	natural	substance[92]	new[92]	_	_
13-10	1683-1700	1,4-naphtoquinone	substance[92]	new[92]	_	_
13-11	1701-1709	moieties	substance[92]	new[92]	_	_
13-12	1710-1720	conjugated	_	_	_	_
13-13	1721-1725	with	_	_	_	_
13-14	1726-1733	glucose	substance|substance[94]	new|giv[94]	coref|coref|coref|coref	14-17|20-16[154_94]|14-17|20-16[154_94]
13-15	1734-1742	residues	substance[94]	giv[94]	_	_
13-16	1743-1746	via	substance[94]	giv[94]	_	_
13-17	1747-1760	non-glycoside	substance[94]|abstract[95]	giv[94]|new[95]	coref	16-18[0_95]
13-18	1761-1765	bond	substance[94]|abstract[95]	giv[94]|new[95]	_	_
13-19	1766-1768	at	substance[94]|abstract[95]	giv[94]|new[95]	_	_
13-20	1769-1771	C6	substance[94]|abstract[95]|object|abstract[97]	giv[94]|new[95]|new|new[97]	coref|coref|coref|coref	15-14[109_97]|16-7|15-14[109_97]|16-7
13-21	1772-1780	position	substance[94]|abstract[95]|abstract[97]	giv[94]|new[95]|new[97]	_	_
13-22	1781-1782	.	_	_	_	_

#Text=The non-glycoside nature of the conjugates was chosen in order to provide the highest affinity to glucose transporters located in the cellular membrane .
14-1	1783-1786	The	abstract[98]	new[98]	_	_
14-2	1787-1800	non-glycoside	abstract[98]	new[98]	_	_
14-3	1801-1807	nature	abstract[98]	new[98]	_	_
14-4	1808-1810	of	abstract[98]	new[98]	_	_
14-5	1811-1814	the	abstract[98]|object[99]	new[98]|giv[99]	coref	20-8[152_99]
14-6	1815-1825	conjugates	abstract[98]|object[99]	new[98]|giv[99]	_	_
14-7	1826-1829	was	_	_	_	_
14-8	1830-1836	chosen	_	_	_	_
14-9	1837-1839	in	_	_	_	_
14-10	1840-1845	order	_	_	_	_
14-11	1846-1848	to	_	_	_	_
14-12	1849-1856	provide	_	_	_	_
14-13	1857-1860	the	abstract[100]	new[100]	coref	17-4[126_100]
14-14	1861-1868	highest	abstract[100]	new[100]	_	_
14-15	1869-1877	affinity	abstract[100]	new[100]	_	_
14-16	1878-1880	to	abstract[100]	new[100]	_	_
14-17	1881-1888	glucose	abstract[100]|substance|abstract[102]	new[100]|giv|new[102]	coref|coref	16-10|16-10
14-18	1889-1901	transporters	abstract[100]|abstract[102]	new[100]|new[102]	_	_
14-19	1902-1909	located	_	_	_	_
14-20	1910-1912	in	_	_	_	_
14-21	1913-1916	the	place[103]	new[103]	ana	15-1[0_103]
14-22	1917-1925	cellular	place[103]	new[103]	_	_
14-23	1926-1934	membrane	place[103]	new[103]	_	_
14-24	1935-1936	.	_	_	_	_

#Text=It is known that the presence of free unsubstituted glycoside hydroxyl ( at C1 position ) is important for the stabilization of hydrogen bonding interactions with GLUT-1 and therefore is required for the successful cellular uptake of the sugar-conjugated molecules .
15-1	1937-1939	It	place	giv	_	_
15-2	1940-1942	is	_	_	_	_
15-3	1943-1948	known	_	_	_	_
15-4	1949-1953	that	_	_	_	_
15-5	1954-1957	the	abstract[105]	new[105]	_	_
15-6	1958-1966	presence	abstract[105]	new[105]	_	_
15-7	1967-1969	of	abstract[105]	new[105]	_	_
15-8	1970-1974	free	abstract[105]|substance[107]	new[105]|new[107]	coref	16-4[116_107]
15-9	1975-1988	unsubstituted	abstract[105]|substance[107]	new[105]|new[107]	_	_
15-10	1989-1998	glycoside	abstract[105]|place|substance[107]	new[105]|new|new[107]	_	_
15-11	1999-2007	hydroxyl	abstract[105]|substance[107]	new[105]|new[107]	_	_
15-12	2008-2009	(	abstract[105]|substance[107]	new[105]|new[107]	_	_
15-13	2010-2012	at	abstract[105]|substance[107]	new[105]|new[107]	_	_
15-14	2013-2015	C1	abstract[105]|substance[107]|object|abstract[109]	new[105]|new[107]|new|giv[109]	coref|coref	16-7[118_109]|16-7[118_109]
15-15	2016-2024	position	abstract[105]|substance[107]|abstract[109]	new[105]|new[107]|giv[109]	_	_
15-16	2025-2026	)	abstract[105]|substance[107]	new[105]|new[107]	_	_
15-17	2027-2029	is	_	_	_	_
15-18	2030-2039	important	_	_	_	_
15-19	2040-2043	for	_	_	_	_
15-20	2044-2047	the	abstract[110]	new[110]	_	_
15-21	2048-2061	stabilization	abstract[110]	new[110]	_	_
15-22	2062-2064	of	abstract[110]	new[110]	_	_
15-23	2065-2073	hydrogen	abstract[110]|abstract[111]	new[110]|new[111]	coref	16-16[123_111]
15-24	2074-2081	bonding	abstract[110]|abstract[111]	new[110]|new[111]	_	_
15-25	2082-2094	interactions	abstract[110]|abstract[111]	new[110]|new[111]	_	_
15-26	2095-2099	with	abstract[110]|abstract[111]	new[110]|new[111]	_	_
15-27	2100-2106	GLUT-1	abstract[110]|abstract[111]|substance	new[110]|new[111]|new	coref	17-12
15-28	2107-2110	and	_	_	_	_
15-29	2111-2120	therefore	_	_	_	_
15-30	2121-2123	is	_	_	_	_
15-31	2124-2132	required	_	_	_	_
15-32	2133-2136	for	_	_	_	_
15-33	2137-2140	the	abstract[113]	giv[113]	coref	22-70[189_113]
15-34	2141-2151	successful	abstract[113]	giv[113]	_	_
15-35	2152-2160	cellular	abstract[113]	giv[113]	_	_
15-36	2161-2167	uptake	abstract[113]	giv[113]	_	_
15-37	2168-2170	of	abstract[113]	giv[113]	_	_
15-38	2171-2174	the	abstract[113]|object[114]	giv[113]|giv[114]	_	_
15-39	2175-2191	sugar-conjugated	abstract[113]|object[114]	giv[113]|giv[114]	_	_
15-40	2192-2201	molecules	abstract[113]|object[114]	giv[113]|giv[114]	_	_
15-41	2202-2203	.	_	_	_	_

#Text=In contrast , the hydroxyl at C6 position of glucose molecule is not relevant for the hydrogen bond interactions and therefore it ’s substitution may be more tolerable .
16-1	2204-2206	In	_	_	_	_
16-2	2207-2215	contrast	abstract	new	_	_
16-3	2216-2217	,	_	_	_	_
16-4	2218-2221	the	substance[116]	giv[116]	_	_
16-5	2222-2230	hydroxyl	substance[116]	giv[116]	_	_
16-6	2231-2233	at	substance[116]	giv[116]	_	_
16-7	2234-2236	C6	substance[116]|object|abstract[118]	giv[116]|giv|giv[118]	ana|ana	16-22[0_118]|16-22[0_118]
16-8	2237-2245	position	substance[116]|abstract[118]	giv[116]|giv[118]	_	_
16-9	2246-2248	of	substance[116]|abstract[118]	giv[116]|giv[118]	_	_
16-10	2249-2256	glucose	substance[116]|abstract[118]|substance|abstract[120]	giv[116]|giv[118]|giv|giv[120]	coref|coref|coref|coref	17-7|24-28[207_120]|17-7|24-28[207_120]
16-11	2257-2265	molecule	substance[116]|abstract[118]|abstract[120]	giv[116]|giv[118]|giv[120]	_	_
16-12	2266-2268	is	_	_	_	_
16-13	2269-2272	not	_	_	_	_
16-14	2273-2281	relevant	_	_	_	_
16-15	2282-2285	for	_	_	_	_
16-16	2286-2289	the	abstract[123]	giv[123]	_	_
16-17	2290-2298	hydrogen	substance|abstract[123]	new|giv[123]	_	_
16-18	2299-2303	bond	abstract|abstract[123]	giv|giv[123]	_	_
16-19	2304-2316	interactions	abstract[123]	giv[123]	_	_
16-20	2317-2320	and	_	_	_	_
16-21	2321-2330	therefore	_	_	_	_
16-22	2331-2333	it	abstract	giv	_	_
16-23	2334-2336	’s	_	_	_	_
16-24	2337-2349	substitution	abstract	new	_	_
16-25	2350-2353	may	_	_	_	_
16-26	2354-2356	be	_	_	_	_
16-27	2357-2361	more	_	_	_	_
16-28	2362-2371	tolerable	_	_	_	_
16-29	2372-2373	.	_	_	_	_

#Text=In fact , the affinity of glucose with substituted C6-OH to GLUT-1 was reported to be almost equal to its unsubstituted analogues .
17-1	2374-2376	In	_	_	_	_
17-2	2377-2381	fact	_	_	_	_
17-3	2382-2383	,	_	_	_	_
17-4	2384-2387	the	abstract[126]	giv[126]	_	_
17-5	2388-2396	affinity	abstract[126]	giv[126]	_	_
17-6	2397-2399	of	abstract[126]	giv[126]	_	_
17-7	2400-2407	glucose	abstract[126]|substance	giv[126]|giv	coref	18-12[135_0]
17-8	2408-2412	with	abstract[126]	giv[126]	_	_
17-9	2413-2424	substituted	abstract[126]|substance[128]	giv[126]|new[128]	_	_
17-10	2425-2430	C6-OH	abstract[126]|substance[128]	giv[126]|new[128]	_	_
17-11	2431-2433	to	abstract[126]|substance[128]	giv[126]|new[128]	_	_
17-12	2434-2440	GLUT-1	abstract[126]|substance[128]|substance	giv[126]|new[128]|giv	ana	17-20
17-13	2441-2444	was	_	_	_	_
17-14	2445-2453	reported	_	_	_	_
17-15	2454-2456	to	_	_	_	_
17-16	2457-2459	be	_	_	_	_
17-17	2460-2466	almost	_	_	_	_
17-18	2467-2472	equal	_	_	_	_
17-19	2473-2475	to	_	_	_	_
17-20	2476-2479	its	substance|substance[131]	giv|new[131]	coref|coref	22-38[175_0]|22-38[175_0]
17-21	2480-2493	unsubstituted	substance[131]	new[131]	_	_
17-22	2494-2503	analogues	substance[131]	new[131]	_	_
17-23	2504-2505	.	_	_	_	_

#Text=Therefore , instead of a conventional glycosylation reaction ( results in C1-substituted glucose ) we applied a new reaction of alkylation of 2-hydroxy-1,4-naphthoquinones with 6-deoxy-6-iodo-1,2:3,5-di-O- isopropylidene-α-D-glucofuranose ( results in a C6-substituted glucose ) .
18-1	2506-2515	Therefore	_	_	_	_
18-2	2516-2517	,	_	_	_	_
18-3	2518-2525	instead	abstract[133]	new[133]	appos	18-10[134_133]
18-4	2526-2528	of	abstract[133]	new[133]	_	_
18-5	2529-2530	a	abstract[133]	new[133]	_	_
18-6	2531-2543	conventional	abstract[133]	new[133]	_	_
18-7	2544-2557	glycosylation	abstract|abstract[133]	new|new[133]	_	_
18-8	2558-2566	reaction	abstract[133]	new[133]	_	_
18-9	2567-2568	(	_	_	_	_
18-10	2569-2576	results	abstract[134]	giv[134]	coref	18-28[142_134]
18-11	2577-2579	in	abstract[134]	giv[134]	_	_
18-12	2580-2594	C1-substituted	abstract[134]|substance[135]	giv[134]|giv[135]	coref	18-30[143_135]
18-13	2595-2602	glucose	abstract[134]|substance[135]	giv[134]|giv[135]	_	_
18-14	2603-2604	)	_	_	_	_
18-15	2605-2607	we	person	giv	ana	19-19
18-16	2608-2615	applied	_	_	_	_
18-17	2616-2617	a	abstract[137]	new[137]	coref	19-1[144_137]
18-18	2618-2621	new	abstract[137]	new[137]	_	_
18-19	2622-2630	reaction	abstract[137]	new[137]	_	_
18-20	2631-2633	of	abstract[137]	new[137]	_	_
18-21	2634-2644	alkylation	abstract[137]|substance[138]	new[137]|new[138]	_	_
18-22	2645-2647	of	abstract[137]|substance[138]	new[137]|new[138]	_	_
18-23	2648-2677	2-hydroxy-1,4-naphthoquinones	abstract[137]|substance[138]|substance	new[137]|new[138]|new	_	_
18-24	2678-2682	with	_	_	_	_
18-25	2683-2711	6-deoxy-6-iodo-1,2:3,5-di-O-	substance[140]	new[140]	_	_
18-26	2712-2744	isopropylidene-α-D-glucofuranose	substance[140]|substance	new[140]|new	_	_
18-27	2745-2746	(	_	_	_	_
18-28	2747-2754	results	abstract[142]	giv[142]	coref	19-9[147_142]
18-29	2755-2757	in	abstract[142]	giv[142]	_	_
18-30	2758-2759	a	abstract[142]|substance[143]	giv[142]|giv[143]	coref	20-17[0_143]
18-31	2760-2774	C6-substituted	abstract[142]|substance[143]	giv[142]|giv[143]	_	_
18-32	2775-2782	glucose	abstract[142]|substance[143]	giv[142]|giv[143]	_	_
18-33	2783-2784	)	_	_	_	_
18-34	2785-2786	.	_	_	_	_

#Text=This reaction was more efficient in comparison with transesterification reaction of 2-methoxy-1,4-naphthoquinones , which was recently discovered by us .
19-1	2787-2791	This	abstract[144]	giv[144]	_	_
19-2	2792-2800	reaction	abstract[144]	giv[144]	_	_
19-3	2801-2804	was	_	_	_	_
19-4	2805-2809	more	_	_	_	_
19-5	2810-2819	efficient	_	_	_	_
19-6	2820-2822	in	_	_	_	_
19-7	2823-2833	comparison	abstract[145]	new[145]	_	_
19-8	2834-2838	with	abstract[145]	new[145]	_	_
19-9	2839-2858	transesterification	abstract[145]|abstract|abstract[147]	new[145]|new|giv[147]	_	_
19-10	2859-2867	reaction	abstract[145]|abstract[147]	new[145]|giv[147]	_	_
19-11	2868-2870	of	abstract[145]|abstract[147]	new[145]|giv[147]	_	_
19-12	2871-2900	2-methoxy-1,4-naphthoquinones	abstract[145]|abstract[147]|substance	new[145]|giv[147]|new	_	_
19-13	2901-2902	,	_	_	_	_
19-14	2903-2908	which	_	_	_	_
19-15	2909-2912	was	_	_	_	_
19-16	2913-2921	recently	_	_	_	_
19-17	2922-2932	discovered	_	_	_	_
19-18	2933-2935	by	_	_	_	_
19-19	2936-2938	us	person	giv	ana	20-3
19-20	2939-2940	.	_	_	_	_

#Text=Thus , we synthesized a series of 6-(1,4-naphtoquinonyl)-D-glucose conjugates containing diprotected , monoprotected , or unprotected glucose residues .
20-1	2941-2945	Thus	_	_	_	_
20-2	2946-2947	,	_	_	_	_
20-3	2948-2950	we	person	giv	ana	21-4
20-4	2951-2962	synthesized	_	_	_	_
20-5	2963-2964	a	object[151]	new[151]	_	_
20-6	2965-2971	series	object[151]	new[151]	_	_
20-7	2972-2974	of	object[151]	new[151]	_	_
20-8	2975-3007	6-(1,4-naphtoquinonyl)-D-glucose	object[151]|object[152]	new[151]|giv[152]	coref	22-31[173_152]
20-9	3008-3018	conjugates	object[151]|object[152]	new[151]|giv[152]	_	_
20-10	3019-3029	containing	_	_	_	_
20-11	3030-3041	diprotected	_	_	_	_
20-12	3042-3043	,	_	_	_	_
20-13	3044-3057	monoprotected	_	_	_	_
20-14	3058-3059	,	_	_	_	_
20-15	3060-3062	or	_	_	_	_
20-16	3063-3074	unprotected	substance[154]	giv[154]	_	_
20-17	3075-3082	glucose	substance|substance[154]	giv|giv[154]	coref	22-12
20-18	3083-3091	residues	substance[154]	giv[154]	_	_
20-19	3092-3093	.	_	_	_	_

#Text=In line with our hypotheses the glucose-conjugated compounds revealed higher selectivity towards five human prostate cancer cell lines compared with five non-cancerous lines .
21-1	3094-3096	In	_	_	_	_
21-2	3097-3101	line	_	_	_	_
21-3	3102-3106	with	_	_	_	_
21-4	3107-3110	our	person|abstract[156]	giv|new[156]	_	_
21-5	3111-3121	hypotheses	abstract[156]	new[156]	_	_
21-6	3122-3125	the	substance[157]	giv[157]	coref	22-66[187_157]
21-7	3126-3144	glucose-conjugated	substance[157]	giv[157]	_	_
21-8	3145-3154	compounds	substance[157]	giv[157]	_	_
21-9	3155-3163	revealed	_	_	_	_
21-10	3164-3170	higher	abstract[158]	giv[158]	_	_
21-11	3171-3182	selectivity	abstract[158]	giv[158]	_	_
21-12	3183-3190	towards	abstract[158]	giv[158]	_	_
21-13	3191-3195	five	abstract[158]|object[162]	giv[158]|new[162]	coref	21-21[163_162]
21-14	3196-3201	human	abstract[158]|object[162]	giv[158]|new[162]	_	_
21-15	3202-3210	prostate	abstract[158]|event|object[162]	giv[158]|giv|new[162]	coref	22-41
21-16	3211-3217	cancer	abstract[158]|abstract|object[162]	giv[158]|giv|new[162]	coref	22-42
21-17	3218-3222	cell	abstract[158]|place|object[162]	giv[158]|new|new[162]	_	_
21-18	3223-3228	lines	abstract[158]|object[162]	giv[158]|new[162]	_	_
21-19	3229-3237	compared	_	_	_	_
21-20	3238-3242	with	_	_	_	_
21-21	3243-3247	five	object[163]	giv[163]	_	_
21-22	3248-3261	non-cancerous	object[163]	giv[163]	_	_
21-23	3262-3267	lines	object[163]	giv[163]	_	_
21-24	3268-3269	.	_	_	_	_

#Text=The successful targeting of the Warburg effect by the newly synthesized glucose derivatives is strongly suggested by the following findings : ( a ) correlation of cytotoxicity and selectivity of the synthesized conjugates with higher expression of GLUT-1 in human prostate cancer cells ; ( b ) inhibition of cytotoxicity of the conjugates by addition of glucose to the media ; c ) ability of the compounds to inhibit a glucose uptake by cancer cells .
22-1	3270-3273	The	abstract[164]	new[164]	_	_
22-2	3274-3284	successful	abstract[164]	new[164]	_	_
22-3	3285-3294	targeting	abstract[164]	new[164]	_	_
22-4	3295-3297	of	abstract[164]	new[164]	_	_
22-5	3298-3301	the	abstract[164]|abstract[166]	new[164]|giv[166]	coref	26-10[216_166]
22-6	3302-3309	Warburg	abstract[164]|person|abstract[166]	new[164]|new|giv[166]	_	_
22-7	3310-3316	effect	abstract[164]|abstract[166]	new[164]|giv[166]	_	_
22-8	3317-3319	by	abstract[164]|abstract[166]	new[164]|giv[166]	_	_
22-9	3320-3323	the	abstract[164]|abstract[166]|object[168]	new[164]|giv[166]|giv[168]	coref	24-17[205_168]
22-10	3324-3329	newly	abstract[164]|abstract[166]|object[168]	new[164]|giv[166]|giv[168]	_	_
22-11	3330-3341	synthesized	abstract[164]|abstract[166]|object[168]	new[164]|giv[166]|giv[168]	_	_
22-12	3342-3349	glucose	abstract[164]|abstract[166]|substance|object[168]	new[164]|giv[166]|giv|giv[168]	coref	22-57
22-13	3350-3361	derivatives	abstract[164]|abstract[166]|object[168]	new[164]|giv[166]|giv[168]	_	_
22-14	3362-3364	is	_	_	_	_
22-15	3365-3373	strongly	_	_	_	_
22-16	3374-3383	suggested	_	_	_	_
22-17	3384-3386	by	_	_	_	_
22-18	3387-3390	the	abstract[169]	new[169]	_	_
22-19	3391-3400	following	abstract[169]	new[169]	_	_
22-20	3401-3409	findings	abstract[169]	new[169]	_	_
22-21	3410-3411	:	_	_	_	_
22-22	3412-3413	(	abstract[170]	new[170]	_	_
22-23	3414-3415	a	abstract[170]	new[170]	_	_
22-24	3416-3417	)	abstract[170]	new[170]	_	_
22-25	3418-3429	correlation	abstract[170]	new[170]	_	_
22-26	3430-3432	of	abstract[170]	new[170]	_	_
22-27	3433-3445	cytotoxicity	abstract[170]|abstract	new[170]|new	_	_
22-28	3446-3449	and	abstract[170]	new[170]	_	_
22-29	3450-3461	selectivity	abstract[170]|abstract[172]	new[170]|new[172]	coref	23-21[0_172]
22-30	3462-3464	of	abstract[170]|abstract[172]	new[170]|new[172]	_	_
22-31	3465-3468	the	abstract[170]|abstract[172]|object[173]	new[170]|new[172]|giv[173]	_	_
22-32	3469-3480	synthesized	abstract[170]|abstract[172]|object[173]	new[170]|new[172]|giv[173]	_	_
22-33	3481-3491	conjugates	abstract[170]|abstract[172]|object[173]	new[170]|new[172]|giv[173]	_	_
22-34	3492-3496	with	abstract[170]|abstract[172]|object[173]	new[170]|new[172]|giv[173]	_	_
22-35	3497-3503	higher	abstract[170]|abstract[172]|object[173]|abstract[174]	new[170]|new[172]|giv[173]|new[174]	_	_
22-36	3504-3514	expression	abstract[170]|abstract[172]|object[173]|abstract[174]	new[170]|new[172]|giv[173]|new[174]	_	_
22-37	3515-3517	of	abstract[170]|abstract[172]|object[173]|abstract[174]	new[170]|new[172]|giv[173]|new[174]	_	_
22-38	3518-3524	GLUT-1	abstract[170]|abstract[172]|object[173]|abstract[174]|substance[175]	new[170]|new[172]|giv[173]|new[174]|giv[175]	_	_
22-39	3525-3527	in	abstract[170]|abstract[172]|object[173]|abstract[174]|substance[175]	new[170]|new[172]|giv[173]|new[174]|giv[175]	_	_
22-40	3528-3533	human	abstract[170]|abstract[172]|object[173]|abstract[174]|substance[175]|object[178]	new[170]|new[172]|giv[173]|new[174]|giv[175]|giv[178]	coref	22-74[191_178]
22-41	3534-3542	prostate	abstract[170]|abstract[172]|object[173]|abstract[174]|substance[175]|place|object[178]	new[170]|new[172]|giv[173]|new[174]|giv[175]|giv|giv[178]	coref	25-8
22-42	3543-3549	cancer	abstract[170]|abstract[172]|object[173]|abstract[174]|substance[175]|abstract|object[178]	new[170]|new[172]|giv[173]|new[174]|giv[175]|giv|giv[178]	coref	22-74
22-43	3550-3555	cells	abstract[170]|abstract[172]|object[173]|abstract[174]|substance[175]|object[178]	new[170]|new[172]|giv[173]|new[174]|giv[175]|giv[178]	_	_
22-44	3556-3557	;	abstract[170]|abstract[172]|object[173]|abstract[174]|substance[175]	new[170]|new[172]|giv[173]|new[174]|giv[175]	_	_
22-45	3558-3559	(	abstract[170]|abstract[172]|object[173]|abstract[174]|substance[175]	new[170]|new[172]|giv[173]|new[174]|giv[175]	_	_
22-46	3560-3561	b	abstract[170]|abstract[172]|object[173]|abstract[174]|substance[175]|place	new[170]|new[172]|giv[173]|new[174]|giv[175]|new	_	_
22-47	3562-3563	)	abstract[170]|abstract[172]|object[173]|abstract[174]|substance[175]	new[170]|new[172]|giv[173]|new[174]|giv[175]	_	_
22-48	3564-3574	inhibition	abstract[170]|abstract[172]|object[173]|abstract[174]|substance[175]|abstract[180]	new[170]|new[172]|giv[173]|new[174]|giv[175]|new[180]	_	_
22-49	3575-3577	of	abstract[170]|abstract[172]|object[173]|abstract[174]|substance[175]|abstract[180]	new[170]|new[172]|giv[173]|new[174]|giv[175]|new[180]	_	_
22-50	3578-3590	cytotoxicity	abstract[170]|abstract[172]|object[173]|abstract[174]|substance[175]|abstract[180]|abstract[181]	new[170]|new[172]|giv[173]|new[174]|giv[175]|new[180]|new[181]	coref	24-12[0_181]
22-51	3591-3593	of	abstract[170]|abstract[172]|object[173]|abstract[174]|substance[175]|abstract[180]|abstract[181]	new[170]|new[172]|giv[173]|new[174]|giv[175]|new[180]|new[181]	_	_
22-52	3594-3597	the	abstract[170]|abstract[172]|object[173]|abstract[174]|substance[175]|abstract[180]|abstract[181]	new[170]|new[172]|giv[173]|new[174]|giv[175]|new[180]|new[181]	_	_
22-53	3598-3608	conjugates	abstract[170]|abstract[172]|object[173]|abstract[174]|substance[175]|abstract[180]|abstract[181]	new[170]|new[172]|giv[173]|new[174]|giv[175]|new[180]|new[181]	_	_
22-54	3609-3611	by	abstract[170]|abstract[172]|object[173]|abstract[174]|substance[175]|abstract[180]|abstract[181]	new[170]|new[172]|giv[173]|new[174]|giv[175]|new[180]|new[181]	_	_
22-55	3612-3620	addition	abstract[170]|abstract[172]|object[173]|abstract[174]|substance[175]|abstract[180]|abstract[181]|abstract[182]	new[170]|new[172]|giv[173]|new[174]|giv[175]|new[180]|new[181]|new[182]	_	_
22-56	3621-3623	of	abstract[170]|abstract[172]|object[173]|abstract[174]|substance[175]|abstract[180]|abstract[181]|abstract[182]	new[170]|new[172]|giv[173]|new[174]|giv[175]|new[180]|new[181]|new[182]	_	_
22-57	3624-3631	glucose	abstract[170]|abstract[172]|object[173]|abstract[174]|substance[175]|abstract[180]|abstract[181]|abstract[182]|substance	new[170]|new[172]|giv[173]|new[174]|giv[175]|new[180]|new[181]|new[182]|giv	coref	22-71
22-58	3632-3634	to	abstract[170]|abstract[172]|object[173]|abstract[174]|substance[175]|abstract[180]|abstract[181]|abstract[182]	new[170]|new[172]|giv[173]|new[174]|giv[175]|new[180]|new[181]|new[182]	_	_
22-59	3635-3638	the	abstract[170]|abstract[172]|object[173]|abstract[174]|substance[175]|abstract[180]|abstract[181]|abstract[182]|abstract[184]	new[170]|new[172]|giv[173]|new[174]|giv[175]|new[180]|new[181]|new[182]|new[184]	_	_
22-60	3639-3644	media	abstract[170]|abstract[172]|object[173]|abstract[174]|substance[175]|abstract[180]|abstract[181]|abstract[182]|abstract[184]	new[170]|new[172]|giv[173]|new[174]|giv[175]|new[180]|new[181]|new[182]|new[184]	_	_
22-61	3645-3646	;	abstract[170]|abstract[172]|object[173]|abstract[174]|substance[175]|abstract[180]|abstract[181]	new[170]|new[172]|giv[173]|new[174]|giv[175]|new[180]|new[181]	_	_
22-62	3647-3648	c	abstract[170]|abstract[172]|object[173]|abstract[174]|substance[175]|abstract[180]|abstract[181]|organization	new[170]|new[172]|giv[173]|new[174]|giv[175]|new[180]|new[181]|new	_	_
22-63	3649-3650	)	abstract[170]|abstract[172]|object[173]|abstract[174]|substance[175]|abstract[180]|abstract[181]	new[170]|new[172]|giv[173]|new[174]|giv[175]|new[180]|new[181]	_	_
22-64	3651-3658	ability	abstract[170]|abstract[172]|object[173]|abstract[174]|substance[175]|abstract[180]|abstract[181]|abstract[186]	new[170]|new[172]|giv[173]|new[174]|giv[175]|new[180]|new[181]|new[186]	_	_
22-65	3659-3661	of	abstract[170]|abstract[172]|object[173]|abstract[174]|substance[175]|abstract[180]|abstract[181]|abstract[186]	new[170]|new[172]|giv[173]|new[174]|giv[175]|new[180]|new[181]|new[186]	_	_
22-66	3662-3665	the	abstract[170]|abstract[172]|object[173]|abstract[174]|substance[175]|abstract[180]|abstract[181]|abstract[186]|substance[187]	new[170]|new[172]|giv[173]|new[174]|giv[175]|new[180]|new[181]|new[186]|giv[187]	_	_
22-67	3666-3675	compounds	abstract[170]|abstract[172]|object[173]|abstract[174]|substance[175]|abstract[180]|abstract[181]|abstract[186]|substance[187]	new[170]|new[172]|giv[173]|new[174]|giv[175]|new[180]|new[181]|new[186]|giv[187]	_	_
22-68	3676-3678	to	_	_	_	_
22-69	3679-3686	inhibit	_	_	_	_
22-70	3687-3688	a	abstract[189]	giv[189]	_	_
22-71	3689-3696	glucose	substance|abstract[189]	giv|giv[189]	coref	23-12
22-72	3697-3703	uptake	abstract[189]	giv[189]	_	_
22-73	3704-3706	by	_	_	_	_
22-74	3707-3713	cancer	abstract|object[191]	giv|giv[191]	coref|coref|coref|coref	25-7[210_191]|27-6[220_0]|25-7[210_191]|27-6[220_0]
22-75	3714-3719	cells	object[191]	giv[191]	_	_
22-76	3720-3721	.	_	_	_	_

#Text=In general , the binding of the quinone core with the glucose moiety lead to an increased water solubility and selectivity .
23-1	3722-3724	In	_	_	_	_
23-2	3725-3732	general	abstract	new	_	_
23-3	3733-3734	,	_	_	_	_
23-4	3735-3738	the	object[193]	new[193]	_	_
23-5	3739-3746	binding	object[193]	new[193]	_	_
23-6	3747-3749	of	object[193]	new[193]	_	_
23-7	3750-3753	the	object[193]|place[195]	new[193]|new[195]	_	_
23-8	3754-3761	quinone	object[193]|object|place[195]	new[193]|new|new[195]	_	_
23-9	3762-3766	core	object[193]|place[195]	new[193]|new[195]	_	_
23-10	3767-3771	with	object[193]|place[195]	new[193]|new[195]	_	_
23-11	3772-3775	the	object[193]|place[195]|substance[197]	new[193]|new[195]|new[197]	_	_
23-12	3776-3783	glucose	object[193]|place[195]|substance|substance[197]	new[193]|new[195]|giv|new[197]	coref	25-23
23-13	3784-3790	moiety	object[193]|place[195]|substance[197]	new[193]|new[195]|new[197]	_	_
23-14	3791-3795	lead	_	_	_	_
23-15	3796-3798	to	_	_	_	_
23-16	3799-3801	an	abstract[199]	new[199]	_	_
23-17	3802-3811	increased	abstract[199]	new[199]	_	_
23-18	3812-3817	water	substance|abstract[199]	new|new[199]	_	_
23-19	3818-3828	solubility	abstract[199]	new[199]	_	_
23-20	3829-3832	and	_	_	_	_
23-21	3833-3844	selectivity	abstract	giv	ana	24-7
23-22	3845-3846	.	_	_	_	_

#Text=However , at the same time it resulted in an absolute cytotoxicity decrease when compared to methoxy derivatives , most probably due to the increased polarity of the molecule .
24-1	3847-3854	However	_	_	_	_
24-2	3855-3856	,	_	_	_	_
24-3	3857-3859	at	_	_	_	_
24-4	3860-3863	the	time[201]	new[201]	_	_
24-5	3864-3868	same	time[201]	new[201]	_	_
24-6	3869-3873	time	time[201]	new[201]	_	_
24-7	3874-3876	it	abstract	giv	_	_
24-8	3877-3885	resulted	_	_	_	_
24-9	3886-3888	in	_	_	_	_
24-10	3889-3891	an	abstract[204]	new[204]	_	_
24-11	3892-3900	absolute	abstract[204]	new[204]	_	_
24-12	3901-3913	cytotoxicity	abstract|abstract[204]	giv|new[204]	_	_
24-13	3914-3922	decrease	abstract[204]	new[204]	_	_
24-14	3923-3927	when	_	_	_	_
24-15	3928-3936	compared	_	_	_	_
24-16	3937-3939	to	_	_	_	_
24-17	3940-3947	methoxy	object[205]	giv[205]	_	_
24-18	3948-3959	derivatives	object[205]	giv[205]	_	_
24-19	3960-3961	,	_	_	_	_
24-20	3962-3966	most	_	_	_	_
24-21	3967-3975	probably	_	_	_	_
24-22	3976-3979	due	_	_	_	_
24-23	3980-3982	to	_	_	_	_
24-24	3983-3986	the	abstract[206]	new[206]	ana	25-1[0_206]
24-25	3987-3996	increased	abstract[206]	new[206]	_	_
24-26	3997-4005	polarity	abstract[206]	new[206]	_	_
24-27	4006-4008	of	abstract[206]	new[206]	_	_
24-28	4009-4012	the	abstract[206]|abstract[207]	new[206]|giv[207]	_	_
24-29	4013-4021	molecule	abstract[206]|abstract[207]	new[206]|giv[207]	_	_
24-30	4022-4023	.	_	_	_	_

#Text=It should also be noted that normal prostate cells are known to have an active glycolysis and also consume significant amount of glucose ( reviewed in ) .
25-1	4024-4026	It	abstract	giv	_	_
25-2	4027-4033	should	_	_	_	_
25-3	4034-4038	also	_	_	_	_
25-4	4039-4041	be	_	_	_	_
25-5	4042-4047	noted	_	_	_	_
25-6	4048-4052	that	_	_	_	_
25-7	4053-4059	normal	object[210]	giv[210]	coref	26-3[214_210]
25-8	4060-4068	prostate	place|object[210]	giv|giv[210]	coref	27-7
25-9	4069-4074	cells	object[210]	giv[210]	_	_
25-10	4075-4078	are	_	_	_	_
25-11	4079-4084	known	_	_	_	_
25-12	4085-4087	to	_	_	_	_
25-13	4088-4092	have	_	_	_	_
25-14	4093-4095	an	abstract[211]	new[211]	_	_
25-15	4096-4102	active	abstract[211]	new[211]	_	_
25-16	4103-4113	glycolysis	abstract[211]	new[211]	_	_
25-17	4114-4117	and	_	_	_	_
25-18	4118-4122	also	_	_	_	_
25-19	4123-4130	consume	_	_	_	_
25-20	4131-4142	significant	quantity[212]	new[212]	_	_
25-21	4143-4149	amount	quantity[212]	new[212]	_	_
25-22	4150-4152	of	quantity[212]	new[212]	_	_
25-23	4153-4160	glucose	quantity[212]|substance	new[212]|giv	_	_
25-24	4161-4162	(	_	_	_	_
25-25	4163-4171	reviewed	_	_	_	_
25-26	4172-4174	in	_	_	_	_
25-27	4175-4176	)	_	_	_	_
25-28	4177-4178	.	_	_	_	_

#Text=Thus , these cells may also be affected by the Warburg effect targeting therapeutics in vivo .
26-1	4179-4183	Thus	_	_	_	_
26-2	4184-4185	,	_	_	_	_
26-3	4186-4191	these	object[214]	giv[214]	_	_
26-4	4192-4197	cells	object[214]	giv[214]	_	_
26-5	4198-4201	may	_	_	_	_
26-6	4202-4206	also	_	_	_	_
26-7	4207-4209	be	_	_	_	_
26-8	4210-4218	affected	_	_	_	_
26-9	4219-4221	by	_	_	_	_
26-10	4222-4225	the	abstract[216]	giv[216]	coref	28-10[230_216]
26-11	4226-4233	Warburg	place|abstract[216]	giv|giv[216]	_	_
26-12	4234-4240	effect	abstract[216]	giv[216]	_	_
26-13	4241-4250	targeting	_	_	_	_
26-14	4251-4263	therapeutics	substance	new	_	_
26-15	4264-4266	in	_	_	_	_
26-16	4267-4271	vivo	_	_	_	_
26-17	4272-4273	.	_	_	_	_

#Text=However , frequently patients with advanced prostate cancer have had local treatment for their primary tumors leaving no vital tissue behind .
27-1	4274-4281	However	_	_	_	_
27-2	4282-4283	,	_	_	_	_
27-3	4284-4294	frequently	person[218]	new[218]	ana	27-14[0_218]
27-4	4295-4303	patients	person[218]	new[218]	_	_
27-5	4304-4308	with	person[218]	new[218]	_	_
27-6	4309-4317	advanced	person[218]|abstract[220]	new[218]|giv[220]	_	_
27-7	4318-4326	prostate	person[218]|place|abstract[220]	new[218]|giv|giv[220]	coref	28-8
27-8	4327-4333	cancer	person[218]|abstract[220]	new[218]|giv[220]	_	_
27-9	4334-4338	have	_	_	_	_
27-10	4339-4342	had	_	_	_	_
27-11	4343-4348	local	abstract[221]	giv[221]	_	_
27-12	4349-4358	treatment	abstract[221]	giv[221]	_	_
27-13	4359-4362	for	abstract[221]	giv[221]	_	_
27-14	4363-4368	their	abstract[221]|person|object[223]	giv[221]|giv|giv[223]	coref|coref	28-3|28-3
27-15	4369-4376	primary	abstract[221]|object[223]	giv[221]|giv[223]	_	_
27-16	4377-4383	tumors	abstract[221]|object[223]	giv[221]|giv[223]	_	_
27-17	4384-4391	leaving	_	_	_	_
27-18	4392-4394	no	object[224]	giv[224]	coref	28-6[228_224]
27-19	4395-4400	vital	object[224]	giv[224]	_	_
27-20	4401-4407	tissue	object[224]	giv[224]	_	_
27-21	4408-4414	behind	_	_	_	_
27-22	4415-4416	.	_	_	_	_

#Text=In the patients cytoreduction of the remaining prostate tissue maybe a pleasant side effect in order to avoid local complications .
28-1	4417-4419	In	_	_	_	_
28-2	4420-4423	the	abstract[226]	new[226]	_	_
28-3	4424-4432	patients	person|abstract[226]	giv|new[226]	_	_
28-4	4433-4446	cytoreduction	abstract[226]	new[226]	_	_
28-5	4447-4449	of	abstract[226]	new[226]	_	_
28-6	4450-4453	the	abstract[226]|object[228]	new[226]|giv[228]	_	_
28-7	4454-4463	remaining	abstract[226]|object[228]	new[226]|giv[228]	_	_
28-8	4464-4472	prostate	abstract[226]|abstract|object[228]	new[226]|giv|giv[228]	_	_
28-9	4473-4479	tissue	abstract[226]|object[228]	new[226]|giv[228]	_	_
28-10	4480-4485	maybe	abstract[230]	giv[230]	_	_
28-11	4486-4487	a	abstract[230]	giv[230]	_	_
28-12	4488-4496	pleasant	abstract[230]	giv[230]	_	_
28-13	4497-4501	side	abstract|abstract[230]	giv|giv[230]	_	_
28-14	4502-4508	effect	abstract[230]	giv[230]	_	_
28-15	4509-4511	in	_	_	_	_
28-16	4512-4517	order	_	_	_	_
28-17	4518-4520	to	_	_	_	_
28-18	4521-4526	avoid	_	_	_	_
28-19	4527-4532	local	abstract[231]	new[231]	_	_
28-20	4533-4546	complications	abstract[231]	new[231]	_	_
28-21	4547-4548	.	_	_	_	_
